---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-170277"
form_type: "8-K"
ticker: "RNTX"
cik: "0001420565"
company_name: "Rein Therapeutics, Inc."
filed_at: "2022-06-08T23:59:59+00:00"
generated_at: "2026-06-25T03:28:54.450869+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Aileron Therapeutics fails to regain Nasdaq bid price compliance; granted extension to Dec 5, 2022

## Summary
- Received deficiency notice Dec 2021 for bid price below $1.00; initial 180-day period ended June 6, 2022 without compliance.
- Nasdaq granted additional 180-day period until Dec 5, 2022 to cure, conditional on meeting other listing requirements.
- Company intends to cure deficiency by effecting a reverse stock split if necessary.
- If compliance not achieved by Dec 5, 2022, Nasdaq will issue delisting notification; Company may appeal to Listing Qualifications Panel.

## SEC filing metadata
- accession: 0001193125-22-170277
- form_type: 8-K
- ticker: RNTX
- cik: 0001420565
- company_name: Rein Therapeutics, Inc.
- filed_at: 2022-06-08T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1420565/000119312522170277/0001193125-22-170277-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1420565/000119312522170277/d368711d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-170277
- JSON: https://secwatch.observer/filing/0001193125-22-170277.json
- Plain text: https://secwatch.observer/filing/0001193125-22-170277.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.